<?xml version='1.0' encoding='utf-8'?>
<document id="29384591"><sentence text="A clinically relevant decrease in abiraterone exposure associated with carbamazepine use in a patient with castration-resistant metastatic prostate cancer."><entity charOffset="34-45" id="DDI-PubMed.29384591.s1.e0" text="abiraterone" /><entity charOffset="71-84" id="DDI-PubMed.29384591.s1.e1" text="carbamazepine" /><pair ddi="false" e1="DDI-PubMed.29384591.s1.e0" e2="DDI-PubMed.29384591.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29384591.s1.e0" e2="DDI-PubMed.29384591.s1.e1" /></sentence><sentence text="Decreased abiraterone exposure after introducing carbamazepine"><entity charOffset="10-21" id="DDI-PubMed.29384591.s2.e0" text="abiraterone" /><entity charOffset="49-62" id="DDI-PubMed.29384591.s2.e1" text="carbamazepine" /><pair ddi="false" e1="DDI-PubMed.29384591.s2.e0" e2="DDI-PubMed.29384591.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29384591.s2.e0" e2="DDI-PubMed.29384591.s2.e1" /></sentence><sentence text="" /><sentence text="Abiraterone acetate and carbamazepine"><entity charOffset="0-19" id="DDI-PubMed.29384591.s4.e0" text="Abiraterone acetate" /><entity charOffset="24-37" id="DDI-PubMed.29384591.s4.e1" text="carbamazepine" /><pair ddi="false" e1="DDI-PubMed.29384591.s4.e0" e2="DDI-PubMed.29384591.s4.e0" /><pair ddi="false" e1="DDI-PubMed.29384591.s4.e0" e2="DDI-PubMed.29384591.s4.e1" /></sentence><sentence text="" /><sentence text="A 65-year-old man with metastatic castration resistant prostate cancer, was treated with abiraterone acetate and prednisolone, and received concomitant carbamazepine for treatment of facial neuropathy"><entity charOffset="89-108" id="DDI-PubMed.29384591.s6.e0" text="abiraterone acetate" /><entity charOffset="113-125" id="DDI-PubMed.29384591.s6.e1" text="prednisolone" /><entity charOffset="152-165" id="DDI-PubMed.29384591.s6.e2" text="carbamazepine" /><pair ddi="false" e1="DDI-PubMed.29384591.s6.e0" e2="DDI-PubMed.29384591.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29384591.s6.e0" e2="DDI-PubMed.29384591.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29384591.s6.e0" e2="DDI-PubMed.29384591.s6.e2" /><pair ddi="false" e1="DDI-PubMed.29384591.s6.e1" e2="DDI-PubMed.29384591.s6.e1" /><pair ddi="false" e1="DDI-PubMed.29384591.s6.e1" e2="DDI-PubMed.29384591.s6.e2" /></sentence><sentence text="" /><sentence text="The interaction was confirmed by a decrease in abiraterone exposure &gt;2-fold (area-under-the-curve and trough levels)"><entity charOffset="47-58" id="DDI-PubMed.29384591.s8.e0" text="abiraterone" /></sentence><sentence text=" After discontinuation of carbamazepine therapy, the abiraterone exposure normalized"><entity charOffset="26-39" id="DDI-PubMed.29384591.s9.e0" text="carbamazepine" /><entity charOffset="53-64" id="DDI-PubMed.29384591.s9.e1" text="abiraterone" /><pair ddi="false" e1="DDI-PubMed.29384591.s9.e0" e2="DDI-PubMed.29384591.s9.e0" /><pair ddi="false" e1="DDI-PubMed.29384591.s9.e0" e2="DDI-PubMed.29384591.s9.e1" /></sentence><sentence text=" No alternative causes were found that explain the decrease in abiraterone exposure"><entity charOffset="63-74" id="DDI-PubMed.29384591.s10.e0" text="abiraterone" /></sentence><sentence text="" /><sentence text="Induction of CYP3A and potentially phase I metabolism (SULT2A1) by carbamazepine"><entity charOffset="67-80" id="DDI-PubMed.29384591.s12.e0" text="carbamazepine" /></sentence><sentence text="" /><sentence text="Clinicians and pharmacists should be aware of this clinically relevant interaction" /><sentence text=" The national drug-drug interaction checker does not warn for this interaction, whereas both the Lexicomp® and Micromedex® advice to avoid if possible or to increase the abiraterone dose frequency to twice daily"><entity charOffset="170-181" id="DDI-PubMed.29384591.s15.e0" text="abiraterone" /></sentence><sentence text=" Carbamazepine should not be combined with abiraterone to avoid underexposure and suboptimal therapy"><entity charOffset="1-14" id="DDI-PubMed.29384591.s16.e0" text="Carbamazepine" /><entity charOffset="43-54" id="DDI-PubMed.29384591.s16.e1" text="abiraterone" /><pair ddi="false" e1="DDI-PubMed.29384591.s16.e0" e2="DDI-PubMed.29384591.s16.e0" /><pair ddi="false" e1="DDI-PubMed.29384591.s16.e0" e2="DDI-PubMed.29384591.s16.e1" /></sentence><sentence text=" Therapeutic drug monitoring of abiraterone is useful to guide therapy when drug-drug interactions cannot be avoided"><entity charOffset="32-43" id="DDI-PubMed.29384591.s17.e0" text="abiraterone" /></sentence><sentence text="" /></document>